Mitochondria in cancer metabolism, an organelle whose time has come?

被引：51

作者：

Anderson, Rebecca G. ^{[1
]}

Ghiraldeli, Lais P. ^{[1
]}

Pardee, Timothy S. ^{[1
,2
,3
]}

机构：

[1] Wake Forest Univ, Ctr Comprehens Canc, Dept Canc Biol, Winston Salem, NC 27109 USA

[2] Wake Forest Univ, Ctr Comprehens Canc, Sect Hematol & Oncol, Winston Salem, NC 27109 USA

[3] Rafael Pharmaceut, Newark, NJ USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2018年 / 1870卷 / 01期

关键词：

ACUTE MYELOID-LEUKEMIA; DIVISION INHIBITOR-1 MDIVI-1; CHRONIC LYMPHOCYTIC-LEUKEMIA; ADVANCED SOLID TUMORS; HUMAN OVARIAN-CANCER; DOSE-ESCALATION; PHASE-I; TARGETED INHIBITION; MUTANT IDH2; MOUSE MODEL;

D O I：

10.1016/j.bbcan.2018.05.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Mitochondria have long been controversial organelles in cancer. Early discoveries in cancer metabolism placed much emphasis on cytosolic contributions. Initial debate focused on if mitochondria had a role in cancer formation and progression at all. More recently the contributions of mitochondria to cancer development and progression have become firmly established. This has led to the identification of novel targets and inhibitors being studied as new therapeutic approaches. This review will summarize the role of mitochondria in cancer and highlight several agents under development.

引用

页码：96 / 102

页数：7

共 75 条

[1] REDOX REGULATION OF FOS AND JUN DNA-BINDING ACTIVITY INVITRO [J].

ABATE, C ;

PATEL, L ;

RAUSCHER, FJ ;

CURRAN, T .

SCIENCE, 1990, 249 (4973) :1157-1161

[2] The Bcl-2 apoptotic switch in cancer development and therapy [J].

Adams, J. M. ;

Cory, S. .

ONCOGENE, 2007, 26 (09) :1324-1337

[3] Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site [J].

Aleksandrov, Alexey ;

Simonson, Thomas .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (04) :1114-+

[4] Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial [J].

Alistar, Angela ;

Morris, Bonny B. ;

Desnoyer, Rodwige ;

Klepin, Heidi D. ;

Hosseinzadeh, Keyanoosh ;

Clark, Clancy ;

Cameron, Amy ;

Leyendecker, John ;

D'Agostino, Ralph, Jr. ;

Topaloglu, Umit ;

Boteju, Lakmal W. ;

Boteju, Asela R. ;

Shorr, Rob ;

Zachar, Zuzana ;

Bingham, Paul M. ;

Ahmed, Tamjeed ;

Crane, Sandrine ;

Shah, Riddhishkumar ;

Migliano, John J. ;

Pardee, Timothy S. ;

Miller, Lance ;

Hawkins, Gregory ;

Jin, Guangxu ;

Zhang, Wei ;

Pasche, Boris .

LANCET ONCOLOGY, 2017, 18 (06) :770-778

[5] Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response [J].

Amatangelo, Michael D. ;

Quek, Lynn ;

Shih, Alan ;

Stein, Eytan M. ;

Roshal, Mikhail ;

David, Muriel D. ;

Marteyn, Benoit ;

Farnoud, Noushin Rahnamay ;

de Botton, Stephane ;

Bernard, Olivier A. ;

Wu, Bin ;

Yen, Katharine E. ;

Tallman, Martin S. ;

Papaemmanuil, Elli ;

Penard-Lacronique, Virginie ;

Thakurta, Anjan ;

Vyas, Paresh ;

Levine, Ross L. .

BLOOD, 2017, 130 (06) :732-741

[6]

[Anonymous], 2017, BLOOD S1

[7]

[Anonymous], 1898, ARCH ANAL PHYSL, P393

[8]

[Anonymous], 1970, ORIGIN EUKARYOTIC CE

[9] Mitochondrial Dynamics - Mitochondrial Fission and Fusion in Human Diseases [J].

Archer, Stephen L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (23) :2236-2251

[10] Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment [J].

Bosc, Claudie ;

Selak, Mary A. ;

Sarry, Jean-Emmanuel .

CELL METABOLISM, 2017, 26 (05) :705-707

← 1 2 3 4 5 6 7 8 →